Zenith Technologies appoints serialization director
Carlos Machado, appointed as serialization director, Zenith Technologies.
The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products.
A global life science technology firm, with headquarters in Ireland, has appointed Carlos Machado as serialization director to lead the company’s sales, operations, implementation and post project support services in the US.
The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products from November 2017 in the US and early 2019 in Europe.
Carlos joins Zenith Technologies with significant experience of assisting pharmaceutical manufacturers with track and trace technologies, having worked on more than 75 serialization projects from both an operations and delivery perspective.
In his former role as director of global operations at a leading anti-counterfeiting technology provider, Carlos helped to pioneer the serialization concept and define the future of authentication.
Jim Lehane, director at Zenith Technologies, said: “Serialization is a real challenge for our customers and it’s an important time for us to add further expertise to our team. Carlos’ background in track and trace technologies and his knowledge of the implementation challenges pharmaceutical manufacturers face, make him ideally suited to lead our serialization offering in the US, helping our customers achieve seamless compliance with the new regulations.
“Zenith Technologies has strong partnerships with many of the world’s largest pharmaceutical manufacturers as well as life science companies of all sizes, providing automation consulting and local support services. Carlos’ appointment will help us to take our US offering to the next level.”
Commenting on his appointment, Carlos said: “Serialization is a huge priority for Zenith Technologies as we understand the challenges customers face in addressing supply chain security and preventing the introduction and distribution of counterfeit product into the global marketplace. It is an exciting time to join the firm as we expand our US presence, leveraging our technological experience, sound project management practices, skilled engineers and world-class implementation and support services.
“When it comes to complying with new serialization regulations, the industry, ranging from the top pharmaceutical companies to contract manufacturing organizations (CMOs), understands what needs to be done. The challenge lies in the scale and complexity of the task ahead. In my new position, it is my responsibility to draw on my industry experience and work alongside our customers to simplify the implementation process and provide flawless execution.”
The announcement is the next stage in Zenith Technologies’ goal to assist companies in the US and Europe with the challenge of serialization. The company recently announced a global partnership with software provider SEA Vision to support pharmaceutical companies with the installation and integration of serialization solutions across drug manufacturing sites.
Carlos continued: “Given our combined expertise and remarkable track record, it’s a natural marriage. We will be working exclusively with SEA Vision to improve existing processes and delivery time, implement its technology and systems and enhance the overall customer experience.
“Our organizations are also working towards providing an innovative interactive e-learning environment to assist our customers with serialization training. We are also actively recruiting and adding experienced talent to our serialization taskforce in the US to ensure we can continue to deliver a high level of service at a local level.”
Marco Baietti, commercial director at SEA Vision said: “Carlos provides a unique combination of leadership skills and expertise in the serialization field thanks to his specialist background. We are thrilled to welcome him to the team and look forward to working together to deliver our shared goal to provide the best track & trace solutions and services in the markets that we serve.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.